PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 17, 2025Frontiers in Immunology14 citationsOpen Access

Post-translational governance of NF-κB in cancer immunity: mechanisms and therapeutic horizons

View Full Paper
YHYue HongYFYing FuQLQian Long

Key Points

  • Post-translational modifications of NF-κB play a crucial role in cancer immunity and immune modulation.
  • Phosphorylation, acetylation, ubiquitination, and methylation effectively influence NF-κB's function in immune responses.
  • Emerging therapeutic strategies targeting NF-κB-modifying enzymes hold potential to enhance immunotherapy effectiveness.
  • This review highlights how NF-κB regulation can guide the development of innovative cancer immunotherapies.

Abstract

Nuclear factor-κB (NF-κB) is a central transcriptional orchestrator of inflammation, immune modulation, and tumor progression. Beyond canonical signal transduction, the immunological functions of NF-κB are intricately governed by a spectrum of post-translational modifications (PTMs)—including phosphorylation, acetylation, ubiquitination, and methylation—that fine-tune its activation, nuclear translocation, DNA binding, and transcriptional specificity. In this Review, we explore how these context-dependent PTMs dynamically shape NF-κB’s role in cancer immunity: promoting macrophage polarization, controlling antigen presentation by dendritic cells, regulating T cell exhaustion, and sustaining immunosuppressive networks within the tumor microenvironment. We further delineate how PTM-mediated NF-κB signaling interfaces with immune checkpoint expression—particularly PD-L1 and IDO1—and fuels resistance to immunotherapies. Emerging pharmacological strategies targeting NF-κB-modifying enzymes or degradation via PROTACs hold promise to reprogram the immune landscape. By integrating mechanistic insight with translational potential, we position NF-κB’s post-translational regulation as a fertile axis for next-generation immunotherapeutic innovation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hong et al. (2025) studied this question.

synapsesocial.com/papers/68d45e5831b076d99fa5ea18https://doi.org/10.3389/fimmu.2025.1627084
Ask AI
Helpful
Bookmark
Share
View Full Paper